Soluble MICA and a MICA Variation as Possible Prognostic Biomarkers for HBV-Induced Hepatocellular Carcinoma

Kumar, Vinod; Lo, Paulisally Hau Yi; Sawai, Hiromi; Kato, Naoya; Takahashi, Atsushi; Zhenzhong Deng; Urabe, Yuji; Mbarek, Hamdi; Tokunaga, Katsushi; Tanaka, Yasuhito; Sugiyama, Masaya; Mizokami, Masashi; Muroyama, Ryosuke; Tateishi, Ryosuke; Omata, Masao; Koike, Kazuhiko; Tanikawa, Chizu; Kamatani, Naoyuki; Kubo, Michiaki; Nakamura, Yusuke
September 2012
PLoS ONE;Sep2012, Vol. 7 Issue 9, Special section p1
Academic Journal
MHC class I polypeptide-related chain A (MICA) molecule is induced in response to viral infection and various types of stress. We recently reported that a single nucleotide polymorphism (SNP) rs2596542 located in the MICA promoter region was significantly associated with the risk for hepatitis C virus (HCV)-induced hepatocellular carcinoma (HCC) and also with serum levels of soluble MICA (sMICA). In this study, we focused on the possible involvement of MICA in liver carcinogenesis related to hepatitis B virus (HBV) infection and examined correlation between the MICA polymorphism and the serum sMICA levels in HBV-induced HCC patients. The genetic association analysis revealed a nominal association with an SNP rs2596542; a G allele was considered to increase the risk of HBV-induced HCC (P = 0.029 with odds ratio of 1.19). We also found a significant elevation of sMICA in HBV-induced HCC cases. Moreover, a G allele of SNP rs2596542 was significantly associated with increased sMICA levels (P = 0.009). Interestingly, HCC patients with the high serum level of sMICA (>5 pg/ml) exhibited poorer prognosis than those with the low serum level of sMICA (≤5 pg/ml) (P = 0.008). Thus, our results highlight the importance of MICA genetic variations and the significance of sMICA as a predictive biomarker for HBV-induced HCC.


Related Articles

  • Identification of sequence polymorphism in the D-Loop region of mitochondrial DNA as a risk factor for hepatocellular carcinoma with distinct etiology. Ruixing Zhang; Fengbin Zhang; Cuiju Wang; Shunxiang Wang; Yih-Horng Shiao; Zhanjun Guo // Journal of Experimental & Clinical Cancer Research (17569966);2010, Vol. 29, p130 

    Background: Hepatocellular carcinoma (HCC) is frequently preceded by hepatitis virus infection or alcohol abuse. Genetic backgrounds may increase susceptibility to HCC from these exposures. Methods: Mitochondrial DNA (mtDNA) of peripheral blood, tumor, and/or adjacent non-tumor tissue from 49...

  • Hepatocellular carcinoma arising from ectopic liver tissue in the pancreas. Diana Cardona; Stephen Grobmyer; James Crawford; Chen Liu // Virchows Archiv;Feb2007, Vol. 450 Issue 2, p225 

    Abstract??Liver tissue ectopia is a well-documented phenomenon. Rarely, hepatocellular carcinoma arises from the ectopic liver tissue. In this paper, we report a case of a primary, well-differentiated hepatocellular carcinoma arising from ectopic liver tissue in the pancreas. The patient is a...

  • Hepatocellular Carcinoma Metastatic to the Stomach Presenting as Bleeding Multiple Craterogenic Ulcers. Lynch, Patrick; Green, Linda; Jordan, Paul H.; Graham, David Y. // American Journal of Gastroenterology;Jun1989, Vol. 84 Issue 6, p653 

    A patient with previous resection of primary hepatocellular carcinoma developed upper intestinal bleeding. Pinch biopsy and needle aspiration biopsy of a submucosal antral lesion seen at endoscopy yielded metastatic hepatoma. We believe this to be the first report of the endoscopic appearance of...

  • Treatment of hepatocellular carcinoma by percutaneous interventional methods. Livraghi, Tito // European Radiology;Nov2001, Vol. 11 Issue 11, p2207 

    In the treatment of early and intermediate hepatocellular carcinoma the range of indications for percutaneous ablation techniques is becoming wider than surgery or intra-arterial therapies. Indeed, whereas for some years only patients with up to three small tumours were treated, with the...

  • Transarterial chemoembolization had favorable toxicity profile.  // Hem/Onc Today;11/10/2008, Vol. 9 Issue 20, p26 

    This article deals with a study that assessed the toxicity profile of transarterial chemoembolization at six months and one year after treatment in patients with hepatocellular carcinoma. Particular focus is given to the median age of patients, along with their survival rate. Some of the grade-3...

  • Serum Midkine as a Prognostic Biomarker for Patients With Hepatocellular Carcinoma. Yi-Ju Hung; Lin, Zoe H.Y.; Tsun-I Cheng; Chung-Ting Liang; Tse-Ming Kuo; Kuo-Jang Kao // American Journal of Clinical Pathology;Oct2011, Vol. 136 Issue 4, p594 

    Gene expression profiles of paired hepatocellular carcinoma (HCC) and adjacent noncancerous liver tissue samples revealed preferential expression of midkine in HCC. This finding suggested the clinical usefulness of midkine measurement in serum for monitoring HCC treatment response, recurrence,...

  • THE LIVER WITH CARCINOMA: RESECT OR REMOVE? Jones, D. Michael; Johnson, David A.; Cattau Jr., Edward L. // American Journal of Gastroenterology;Jun1992, Vol. 87 Issue 6, p803 

    Presents a study which demonstrated several principles regarding the chance for long-term survival in patients with hepatocellular carcinoma (HCC). Use of tumors, node and metastases (TNM) staging system to compare the efficacy of various therapies for HCC; Percentage of HCC that recurred in...

  • CT mapping of the distribution of saline during radiofrequency ablation with perfusion electrodes. Gillams, A. R.; Lees, W. R. // CardioVascular & Interventional Radiology;Jul/Aug2005, Vol. 28 Issue 4, p476 

    Purpose: During radiofrequency (RF) ablation, adjunctive saline increases the size of the ablation zone and therefore electrodes that simultaneously deliver current and saline have been developed, but the addition of saline also results in an irregular ablation zone. Our aim was to...

  • What is the best staging system for hepatocellular carcinoma? Kudo, Masatoshi // Journal of Gastroenterology;Mar2006, Vol. 41 Issue 3, p290 

    The article focuses on the best staging system for hepatocellular carcinoma. According to him, the modified Japan Integrated Staging score, which combines the tumor-node-metastasis staging system and the Liver Damage Grade systems developed by the Liver Cancer Study Group of Japan is the best...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics